Regulatory Pathway and Future

FDA Breakthrough, EMA PRIME, and the road from Phase 3 to approval

The Regulatory Landscape

Survodutide holds FDA Breakthrough Therapy designation for MASH and EMA PRIME designation, both of which accelerate the review process. This unit covers the regulatory designations, the Boehringer Ingelheim and Zealand Pharma partnership, the projected approval timeline, and what comes after Phase 3.

Interactive Regulatory Tracker

Explore regulatory designations, milestones, and the path to market approval.

regulatory designation tracker

Knowledge Check

Test your understanding of the regulatory pathway and commercial outlook.

Practice

Apply regulatory and market concepts before the final exam.